AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...

Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

AbbVie (ABBV) stock gains as the company lifts 2025 earnings outlook after strong Q1 results, driven by its newer immunology ...

These five Dividend Aristocrats have the least negligible impact from the tariffs and are ideal for passive income investors.

NYSE ABBV traded up $1.10 during trading hours on Friday, hitting $172.78. 8,474,425 shares of the company were exchanged, compared to its average volume of 5,997,458. The company has a 50 day ...

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential. Total return includes interest, capital ...

It's important to note that if a patient has a folate receptor alpha expression level that meets the criteria for receiving Elahere [mirvetuximab soravtansine], they are required to have received it.